Research and development

Our development pipeline

Veranschaulichung der Projektphasen

Phasen einer klinischen Entwicklung

Weitere Informationen

Biotest’s development projects involve new therapy options in indications with a particularly high medical need. Moreover, the focus is also on further developing already authorised medicines with the aim of opening up other areas of use or making administration easier and more comfortable for the patient. You will find a summary of our current research and development projects here.

By clicking on the name you will obtain further information about the individual projects.

Our development pipeline

Therapeutic Area

All

Haematology

Clinical immunology

Intensive care medicine

Active substance

Indication

Phase

Active substance & Indication

Phase

   
  • pre
  • 1
  • 2
  • 3
  • reg
  • launch
  • lcm
 

Tregalizumab
BT-061

other diseases

Tregalizumab

BT-061
other diseases

 

Indatuximab Ravtansine
BT-062

Multiple myeloma

Indatuximab Ravtansine

BT-062
Multiple myeloma

 

Indatuximab Ravtansine*
BT-062

Solid tumors

Indatuximab Ravtansine*

BT-062
Solid tumors

 

BT-063

Systemic lupus erythematosus

BT-063
Systemic lupus erythematosus

 

IgM Concentrate
BT-086

Severe community acquired pneumonia

IgM Concentrate

BT-086
Severe community acquired pneumonia

 

Fibrinogen
BT-524

Congenital fibrinogen deficiency

Fibrinogen

BT-524
Congenital fibrinogen deficiency

 

Civacir®
Civacir

Prophylaxis hepatitis C reinfection

Civacir®

Civacir
Prophylaxis hepatitis C reinfection

 

Cytotect 70
BT-084

Congenital CMV infection prophylaxis

Cytotect 70

BT-084
Congenital CMV infection prophylaxis